Blog Archives

Top 5 News: 12/4-12/11

Top 5 logo1) Baxalta wins FDA approval with a treatment for a rare bleeding disease FierceBiotech, 12/8/2015
Baxalta ($BXLT) picked up FDA approval for a drug that treats von Willebrand disease, a rare inherited bleeding disorder that results from a missing protein.
Link

2) For Epizyme chief executive, the work is personalBoston Globe, 12/4/2015
Epizyme Inc.’s new chief executive Robert Bazemore understands the disease his company is targeting only too well. When he was introduced to employees this summer, Bazemore surprised them by disclosing that he’s a survivor of non-Hodgkin’s lymphoma, a life-threatening blood cancer that could potentially be treated by the company’s lead drug candidate.
Link

3) Novo Nordisk partners with IBM Watson Health to develop diabetes management tools BBJ, 12/10/2015
Novo Nordisk plans to use IBM Watson Health to analyze its data on patients with diabetes, announcing today an agreement with the IBM subsidiary.
Link

4) Drug may give those leaving jail a better shot at recovery – Boston Globe, 12/9/2015
But the drug itself may not be the real game-changer, said Dr. Barbara Herbert, president of the Massachusetts chapter of the American Society of Addiction Medicine. More crucial, she said, are efforts by the manufacturer, Waltham drug maker Alkermes, to push prisons to link departing inmates with services on the outside, measures often lacking in the past.
Link

5) FDA approves Alexion drug for ultra-rare disease – Reuters, 12/8/2015
The U.S. Food and Drug Administration on Tuesday approved Alexion Pharmaceutical Inc’s treatment for an ultra-rare and potentially fatal genetic disorder.
Link

Top 5 News Stories 6/1-6/8

1. Vertex, Epizyme, Rib-X named best places to work Mass High Tech – 6/4/12

The Scientist magazine’s yearly Best Places to Work awards have often shone a light on New England companies and this year is no exception. Little Cambridge, Mass-based personalized medicine company Epizyme, with 45 employees, nabbed the number 2 spot nationwide, while its neighbor, the much larger Vertex Pharmaceuticals (Nasdaq: VRTX), with 2047 workers, scored the number 5 spot. Link

2. Boston Biotech Industry Takes Center Stage at the 2012 BIO International Convention Market Watch – 6/5/12

The 2012 BIO International Convention will return to Boston, Mass. for the global event for biotechnology, which will take place June 18-21, 2012 at the Boston Convention and Exhibition Center. Link

3. WPI gets $3M NSF grant for biofabrication program Mass High Tech – 6/6/12

Worcester Polytechnic Institute (WPI) has received a five-year, $3 million award from the National Science Foundation (NSF) to launch a graduate program in biofabrication geared toward turning students into innovators.  Link

Read the rest of this entry